502 related articles for article (PubMed ID: 32541921)
1. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Feng J; Lu PZ; Zhu GZ; Hooi SC; Wu Y; Huang XW; Dai HQ; Chen PH; Li ZJ; Su WJ; Han CY; Ye XP; Peng T; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Jan; 42(1):160-170. PubMed ID: 32541921
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
[TBL] [Abstract][Full Text] [Related]
3. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
[TBL] [Abstract][Full Text] [Related]
4. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
Li J; Li Y; Wang D; Liao R; Wu Z
J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
[TBL] [Abstract][Full Text] [Related]
5. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
7. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.
Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J
J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968
[TBL] [Abstract][Full Text] [Related]
8. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
[TBL] [Abstract][Full Text] [Related]
9. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
[TBL] [Abstract][Full Text] [Related]
10. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
11. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
[TBL] [Abstract][Full Text] [Related]
12. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
Hu Y; Luo Z; Cai S; Xie Q; Zheng S
Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
[TBL] [Abstract][Full Text] [Related]
16. ACSL4 promotes malignant progression of Hepatocellular carcinoma by targeting PAK2 transcription.
Wu D; Zuo Z; Sun X; Li X; Yin F; Yin W
Biochem Pharmacol; 2024 Jun; 224():116206. PubMed ID: 38615921
[TBL] [Abstract][Full Text] [Related]
17. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
Wang P; Jiang Z; Liu X; Yu K; Wang C; Li H; Zhong L
Cancer Med; 2020 Oct; 9(19):6972-6983. PubMed ID: 32779397
[TBL] [Abstract][Full Text] [Related]
18. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
[No Abstract] [Full Text] [Related]
20. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]